Moreover, a study showed that Hb levels increased after treatment with an inhibitor of HIF-PH, while endogenous erythropoietin remained within the normal physiological range (Flamme et al., 2014), which suggests that HIF-PHIs may use a mechanism different from ESAs to improve anemia. Here, GSTM1 is linked to anemia (phenotype).